Sensitivity to MPTP is not increased in Parkinson's disease‐associated mutant α‐synuclein transgenic mice: RAPID COMMUNICATION

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

Betarbet, R., Sherer, T., Mackenzie, G., Garcia-Osuna, M., Panov, A., & Greenamyre, J. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,797 · see citing works

A Drosophila model of Parkinson's disease

Feany, M., & Bender, W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,145 · see citing works

Dopaminergic Loss and Inclusion Body Formation in α-Synuclein Mice: Implications for Neurodegenerative Disorders

Masliah, E., Rockenstein, E. M., Veinbergs, I., Mallory, M. E., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,763 · see citing works

Neuropathology of Parkinson's Disease

Forno, L. (1996) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199603000-00001 · Cited by 1,556 · see citing works

Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias

West, M. J. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01362-9 · Cited by 814 · see citing works

Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease

Hartmann, A., Hunot, S., Michel, P. P., Muriel, M., Vyas, S., Faucheux, B. A., Prigent, A., Turmel, H., Srinivasan, A. N., Ruberg, M., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040556597 · Cited by 717 · see citing works

Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain

Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Schindzielorz, A., Okochi, M., Leimer, U., van der Putten, H., Probst, A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-17-06365.2000 · Cited by 641 · see citing works

Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

Przedborski, S., Jackson-Lewis, V. R., Yokoyama, R., Shibata, T., Dawson, V. L., & Dawson, T. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4565 · Cited by 624 · see citing works

Mutant and Wild Type Human α-Synucleins Assemble into Elongated Filaments with Distinct Morphologies in Vitro

Giasson, B. I., Uryu, K., Trojanowski, J. Q., & Lee, V. M. ‐. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.7619 · Cited by 505 · see citing works

Neuropathology in mice expressing human alpha-synuclein

van der Putten, H., Wiederhold, K., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P. J. M., Rüegg, M. A., et al. (2000) · PubMed Central · doi:10.5451/unibas-ep2767 · Cited by 505 · see citing works

Neuropathology in Mice Expressing Human α-Synuclein

van der Putten, H., Wiederhold, K., Probst, A., Barbieri, S., Mistl, C., Danner, S., Kauffmann, S., Hofele, K., Spooren, W. P. J. M., Rüegg, M. A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06021.2000 · Cited by 478 · see citing works

In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining

Tatton, N. A., & Kish, S. J. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00545-3 · Cited by 469 · see citing works

Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice

Schulz, J. B., Matthews, R. T., Muqit, M. M. K., Browne, S. E., & Beal, M. F. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64020936.x · Cited by 417 · see citing works

α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP

Vila, M., Vukosavić, S., Jackson-Lewis, V. R., Neystat, M., Jakowec, M. W., & Przedborski, S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.740721.x · Cited by 388 · see citing works

Protection by Synergistic Effects of Adenovirus-Mediated X-Chromosome-Linked Inhibitor of Apoptosis and Glial Cell Line-Derived Neurotrophic Factor Gene Transfer in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease

Eberhardt, O., von Coelln, R., Kügler, S., Lindenau, J. H., Rathke‐Hartlieb, S., Gerhardt, E., Haid, S., Isenmann, S., Gravel, C., Srinivasan, A. N., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09126.2000 · Cited by 206 · see citing works

Expression in brain of amyloid precursor protein mutated in the alpha‐secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice.

Moechars, D., Lorent, K., De Strooper, B., Dewachter, I., & Van Leuven, F. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00468.x · Cited by 201 · see citing works

Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity

Tabrizi, S. J. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2683 · Cited by 197 · see citing works

Oxidative post‐translational modifications of α‐synuclein in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse model of Parkinson's disease

Przedborski, S., Chen, Q., Vila, M., Giasson, B. I., Djaldatti, R., Vukosavić, S., Souza, J. M., Jackson-Lewis, V. R., Lee, V. M. ‐., & Ischiropoulos, H. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00174.x · Cited by 190 · see citing works

4.5 kb of the rat tyrosine hydroxylase 5′ flanking sequence directs tissue specific expression during development and contains consensus sites for multiple transcription factors

Schimmel, J. J., Crews, L., Roffler-Tarlov, S. K., & Chikaraishi, D. M. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00234-x · Cited by 76 · see citing works

Detection of DNA base-excision repair activity for oxidative lesions in adult rat brain mitochondria

Chen, D., Lan, J. Q., Pei, W., & Chen, J. (2000) · Journal of Neuroscience Research · doi:10.1002/1097-4547(20000715)61:2 · Cited by 47 · see citing works

DNA regulatory sequences of the rat tyrosine hydroxylase gene direct correct catecholaminergic cell-type specificity of a human growth hormone reporter in the CNS of transgenic mice causing a dwarf phenotype

Banerjee, S. A., Roffler-Tarlov, S. K., Szabó, M., Frohman, L. A., & Chikaraishi, D. M. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90121-x · Cited by 38 · see citing works

Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein

Lotharius, J., & Brundin, P. (2002) · Nature reviews. Neuroscience · doi:10.1038/nrn983 · Cited by 1,283 · see citing works

Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System

Kirik, D., Rosenblad, C., Bürger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02780.2002 · Cited by 730 · see citing works

Mitochondrial dysfunction in Parkinson's disease

Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688 · see citing works

Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences

Exner, N., Lutz, A. K., Haass, C., & Winklhofer, K. F. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.170 · Cited by 652 · see citing works

Expression of A53T Mutant But Not Wild-Type α-Synuclein in PC12 Cells Induces Alterations of the Ubiquitin-Dependent Degradation System, Loss of Dopamine Release, and Autophagic Cell Death

Stefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D. L., & Greene, L. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09549.2001 · Cited by 569 · see citing works

Parkin Protects against the Toxicity Associated with Mutant α-Synuclein

Petrucelli, L., O’Farrell, C., Lockhart, P. J., Baptista, M. J., Kehoe, K. J., Vink, L., Choi, P., Wolozin, B. L., Farrer, M. J., Hardy, J., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)01125-x · Cited by 552 · see citing works

Parkinson’s disease: animal models and dopaminergic cell vulnerability

Blesa, J., & Przedborski, S. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00155 · Cited by 483 · see citing works

Synuclein activates microglia in a model of Parkinson's disease

Su, X., Maguire-Zeiss, K. A., Giuliano, R., Prifti, L., Venkatesh, K., & Federoff, H. J. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.006 · Cited by 474 · see citing works

Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease

Kirik, D., Annett, L. E., Bürger, C., Muzyczka, N., Mandel, R. J., & Björklund, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536383100 · Cited by 404 · see citing works

Misfolded proteinase K–resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies

Neumann, M., Kahle, P. J., Giasson, B. I., Ozmen, L., Borroni, E., Spooren, W. P. J. M., Müller, V., Odoy, S., Fujiwara, H., Hasegawa, M., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15777 · Cited by 351 · see citing works

The role of α-synuclein in Parkinson's disease: insights from animal models

Lad, E. M., Dass, B., Collier, T. J., Kordower, J. H., & Steece‐Collier, K. (2003) · Nature reviews. Neuroscience · doi:10.1038/nrn1199 · Cited by 349 · see citing works

Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line

Lotharius, J., Barg, S., Wiekop, P., Lundberg, C., Raymon, H. K., & Brundin, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205518200 · Cited by 349 · see citing works

Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human α-Synuclein(1–120): Implications for Lewy Body Disorders

Tofaris, G. K., Garcia-Reitboeck, P., Humby, T., Lambourne, S. L., O’Connell, M. T., Ghetti, B. F., Gossage, H., Emson, P. C., Wilkinson, L. S., Goedert, M., et al. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4965-05.2006 · Cited by 325 · see citing works

Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease

Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 303 · see citing works

Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice

Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285 · see citing works

Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease

Lotharius, J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2395 · Cited by 267 · see citing works

Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease

Dev, K. K. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00140-0 · Cited by 262 · see citing works

α-Synuclein Overexpression Protects against Paraquat-Induced Neurodegeneration

Manning-Bog, A., McCormack, A. L., Purisai, M. G., Bolin, L. M., & Monte, D. A. D. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-08-03095.2003 · Cited by 239 · see citing works

Dopaminergic Cell Loss Induced by Human A30P α -Synuclein Gene Transfer to the Rat Substantia Nigra

Klein, R. L., King, M. A., Hamby, M. E., & Meyer, E. M. (2002) · Human Gene Therapy · doi:10.1089/10430340252837206 · Cited by 209 · see citing works

Reverse engineering Lewy bodies: how far have we come and how far can we go?

Fares, M. B., Jagannath, S., & Lashuel, H. A. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-020-00416-6 · Cited by 199 · see citing works

The role of α-synuclein in neurodegenerative diseases

Bennett, M. C. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.010 · Cited by 195 · see citing works

Neurotoxic in vivo models of Parkinson’s disease

Cannon, J. R., & Greenamyre, J. T. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84002-6 · Cited by 192 · see citing works

Gene–environment interactions in Parkinson's disease: Specific evidence in humans and mammalian models

Cannon, J. R., & Greenamyre, J. T. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.06.025 · Cited by 191 · see citing works

MPTP: a review of its mechanisms of neurotoxicity

Przedborski, S., & Vila, M. (2001) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(01)00019-6 · Cited by 191 · see citing works

Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect

Levine, M. S., Cepeda, C., Hickey, M. A., Fleming, S. M., & Chesselet, M. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.08.008 · Cited by 182 · see citing works

Motor dysfunction and gliosis with preserved dopaminergic markers in human α-synuclein A30P transgenic mice

Gómez‐Isla, T., Irizarry, M. C., Mariash, A., Cheung, B. S., Soto, O., Schrump, S. E., Sondel, J., Kotilinek, L., Day, J., Schwarzschild, M. A., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00091-x · Cited by 179 · see citing works

Genes, proteins, and neurotoxins involved in Parkinson’s disease

Halbach, O. V. B. U., Schober, A., & KRIEGLSTEIN, K. G. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.002 · Cited by 178 · see citing works

Risk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice

Thiruchelvam, M. J., Powers, J. M., Cory‐Slechta, D. A., & Richfield, E. K. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03139.x · Cited by 174 · see citing works

Valproic Acid is Neuroprotective in the Rotenone Rat Model of Parkinson’s Disease: Involvement of α-Synuclein

Monti, B., Gatta, V., Piretti, F., Raffaelli, S. S., Virgili, M., & Contestabile, A. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9090-5 · Cited by 172 · see citing works

α-Synuclein Negatively Regulates Protein Kinase Cδ Expression to Suppress Apoptosis in Dopaminergic Neurons by Reducing p300 Histone Acetyltransferase Activity

Jin, H., Kanthasamy, A., Ghosh, A., Yang, Y., Anantharam, V., & Kanthasamy, A. G. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5634-10.2011 · Cited by 164 · see citing works

Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of γ‐synuclein, α‐synuclein and double α/γ‐synuclein null mutant mice

Robertson, D. C., Schmidt, O., Ninkina, N. N., Jones, P. A., Sharkey, J., & Buchman, V. L. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02378.x · Cited by 154 · see citing works

Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

Schlüter, O. M., Fornai, F., Alessandri, M., TAKAMORI, S., Geppert, M., Jahn, R., & Südhof, T. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00036-8 · Cited by 145 · see citing works

Genetics of parkinsonism

Gwinn, K. A. (2002) · Movement Disorders · doi:10.1002/mds.10173 · Cited by 139 · see citing works

MPTP

Speciale, S. G. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00222-2 · Cited by 132 · see citing works

Mutual exacerbation of peroxisome proliferator‐activated receptor γ coactivator 1α deregulation and α‐synuclein oligomerization

Eschbach, J., von Einem, B., Müller, K., Bayer, H., Scheffold, A., Morrison, B. E., Rudolph, K. L., Thal, D. R., Witting, A., Weydt, P., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24294 · Cited by 126 · see citing works

α-Synucleinopathy models and human neuropathology: similarities and differences

Kahle, P. J. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0302-x · Cited by 126 · see citing works

The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I

Litvan, I., Halliday, G. M., Hallett, M., Goetz, C. G., Rocca, W. A., Duyckaerts, C. J., Ben‐Shlomo, Y., Dickson, D. W., Lang, A. E., Chesselet, M., et al. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3180415e42 · Cited by 122 · see citing works

Neuropathology and Neurodegeneration in Rodent Brain Induced by Lentiviral Vectormediated Overexpression of α‐Synuclein

Lauwers, E., Debyser, Z., Dorpe, J. V., Strooper, B. D., Nuttin, B., & Baekelandt, V. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00035.x · Cited by 116 · see citing works

Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?

Maguire‐Zeiss, K. A., Short, D. W., & Federoff, H. J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.09.014 · Cited by 111 · see citing works

Transgenic Models of α‐Synuclein Pathology

Hashimoto, M., Rockenstein, E. M., & Masliah, E. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07475.x · Cited by 108 · see citing works

Neurobiology of α-Synuclein

Vekrellis, K., Rideout, H. J., & Stefanis, L. (2004) · Molecular Neurobiology · doi:10.1385/mn:30:1:001 · Cited by 105 · see citing works

The usual suspects, dopamine and alpha‐synuclein, conspire to cause neurodegeneration

Mor, D. E., Daniels, M. J., & Ischiropoulos, H. (2019) · Movement Disorders · doi:10.1002/mds.27607 · Cited by 103 · see citing works

Increased sensitivity to MPTP in human α-synuclein A30P transgenic mice

Nieto, M., Gil-Bea, F. J., Dalfó, E., Cuadrado‐Tejedor, M., Cabodevilla, F., Sánchez, B., Catena, S., Sesma, T., Ribé, E. M., Ferrer, I., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.010 · Cited by 100 · see citing works

Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human α-synuclein

Yavich, L., Oksman, M., Tanila, H., Kerokoski, P., Hiltunen, M. O., van Groen, T., Puoliväli, J. T., Männistö, P. T., Garcia-Horsman, A., MacDonald, E., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.010 · Cited by 99 · see citing works

Etiology of Parkinson's disease: Genetics and environment revisited

Steece‐Collier, K., Lad, E. M., & Kordower, J. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242594999 · Cited by 99 · see citing works

Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease

Trancikova, A. K., Tsika, E., & Moore, D. J. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4200 · Cited by 92 · see citing works

Using human neural stem cells to model neurological disease

Jakel, R. J., Schneider, B. L., & Svendsen, C. N. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1268 · Cited by 91 · see citing works

Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases

Schildknecht, S. (2013) · ALTEX · doi:10.14573/altex.2013.4.427 · Cited by 85 · see citing works

Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background

Cabin, D. E., Gispert-Sánchez, S., Murphy, D., Auburger, G. W. J., Myers, R. R., & Nussbaum, R. L. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.026 · Cited by 85 · see citing works

Structure/function of α‐synuclein in health and disease: rational development of animal models for Parkinson's and related diseases

Kahle, P. J., Haass, C., Kretzschmar, H. A., & Neumann, M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01020.x · Cited by 85 · see citing works

Oxidative Stress in Genetic Mouse Models of Parkinson’s Disease

Varçin, M., Bentea, E., Michotte, Y. M., & Sarre, S. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/624925 · Cited by 84 · see citing works

In vivo models of alpha-synuclein transmission and propagation

Recasens, A., Ulusoy, A., Kahle, P. J., Monte, D. A. D., & Dehay, B. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2730-9 · Cited by 72 · see citing works

Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson’s Disease and Dopa-Responsive Dystonia

Kawahata, I., & Fukunaga, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113779 · Cited by 71 · see citing works

Gene–Environment Interactions in Parkinson's Disease: The Importance of Animal Modeling

Horowitz, M. P., & Greenamyre, J. T. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.138 · Cited by 71 · see citing works

Resistance to MPTP-Neurotoxicity in α-Synuclein Knockout Mice Is Complemented by Human α-Synuclein and Associated with Increased β-Synuclein and Akt Activation

Thomas, B., Mandir, A. S., West, N. C., Liu, Y., Andrabi, S. A., Stirling, W. L. H., Dawson, V. L., Dawson, T. M., & Lee, M. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016706 · Cited by 68 · see citing works

Expression of mutant ??-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro

Lehmensiek, V., Tan, E.-M., Schwarz, J., & Storch, A. (2002) · Neuroreport · doi:10.1097/00001756-200207190-00013 · Cited by 59 · see citing works

Convergent Pathobiologic Model of Parkinson's Disease

Maguire‐Zeiss, K. A., & Federoff, H. J. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07473.x · Cited by 58 · see citing works

Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse

Taylor, T. N., Potgieter, D., Anwar, S., Senior, S. L., Janezic, S., Threlfell, S., Ryan, B. J., Parkkinen, L., Deltheil, T., Cioroch, M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.10.005 · Cited by 56 · see citing works

Model fusion: The next phase in developing animal models for parkinson’s disease

Manning-Bog, A., & Langston, J. W. (2007) · Neurotoxicity Research · doi:10.1007/bf03033569 · Cited by 56 · see citing works

Alpha Synuclein in Parkinson’s Disease

Kragh, C. L., Romero‐Ramos, M., Halliday, G. M., & Jensen, P. H. (2014) · Springer eBooks · doi:10.1007/978-1-4614-5836-4_14 · Cited by 48 · see citing works

Overexpression of Parkinson's disease‐associated α‐SynucleinA53T by recombinant adeno‐associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP

Dong, Z., Ferger, B., Feldon, J., & Büeler, H. (2002) · Journal of Neurobiology · doi:10.1002/neu.10094 · Cited by 47 · see citing works

DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson's disease

Hegde, M. L. (2009) · Frontiers in bioscience · doi:10.2741/3628 · Cited by 46 · see citing works

Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse

Song, L.-K., Ma, K., Yuan, Y., Mu, Z., Song, X., Niu, F., Han, N., & Chen, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131281 · Cited by 45 · see citing works

Differential cytotoxicity of dopamine and H2O2 in a human neuroblastoma divided cell line transfected with α-synuclein and its familial Parkinson's disease-linked mutants

Wersinger, C., & Sidhu, A. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00212-x · Cited by 45 · see citing works

The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II

Litvan, I., Chesselet, M., Gasser, T., Monte, D. A. D., Parker, D., Hagg, T., Hardy, J., Jenner, P. G., Myers, R. H., Price, D. D., et al. (2007) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318053716a · Cited by 45 · see citing works

Viral Vector Mediated Overexpression of Human α-Synuclein in the Nigrostriatal Dopaminergic Neurons: A New Model for Parkinson's Disease

Maingay, M., Romero‐Ramos, M., & Kirik, D. (2005) · CNS Spectrums · doi:10.1017/s1092852900010075 · Cited by 44 · see citing works

Altered short-term hippocampal synaptic plasticity in mutant α-synuclein transgenic mice

Steidl, J. V., Gómez‐Isla, T., Mariash, A., Ashe, K. H., & Boland, L. M. (2003) · Neuroreport · doi:10.1097/00001756-200302100-00012 · Cited by 44 · see citing works

Genetic factors involved in the pathogenesis of Parkinson's disease

Lee, F. J. S., & Liu, F. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.02.001 · Cited by 43 · see citing works

α-Synuclein nonhuman primate models of Parkinson’s disease

Marmion, D. J., & Kordower, J. H. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1720-0 · Cited by 42 · see citing works

Influence of Different Promoters on the Expression Pattern of Mutated Human α-Synuclein in Transgenic Mice

Maskri, L., Zhu, X., Fritzen, S., Kühn, K., Ullmer, C., Engels, P., Andriske, M., Stichel, C. C., & Lübbert, H. (2004) · Neurodegenerative Diseases · doi:10.1159/000085064 · Cited by 41 · see citing works

Increased Dopaminergic Neuron Sensitivity to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Transgenic Mice Expressing Mutant A53T α-Synuclein

Yu, W. H., Matsuoka, Y., Sziráki, I., Hashim, A., LaFrancois, J. J., Sershen, H. W., & Duff, K. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9533-4 · Cited by 41 · see citing works

Early and late molecular events in neurodegeneration and neuroprotection in Parkinson’s disease MPTP model as assessed by cDNA microarray; the role of iron

Youdim, M. B. H., Grünblatt, E., Levites, Y., Maor, G., & Mandel, S. A. (2002) · Neurotoxicity Research · doi:10.1080/1029842021000045507 · Cited by 39 · see citing works

Transgenic animal models of neurodegeneration based on human genetic studies

Harvey, B. K., Richie, C. T., Hoffer, B. J., & Airavaara, M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0476-6 · Cited by 38 · see citing works

Synucleins and their relationship to Parkinson’s disease

Halbach, O. V. B. U. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0921-7 · Cited by 37 · see citing works

α-Synuclein and nonhuman primate models of Parkinson's disease

Vermilyea, S., & Emborg, M. E. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.07.025 · Cited by 37 · see citing works

Trichloroethylene and its metabolite TaClo lead to degeneration of substantia nigra dopaminergic neurones: Effects in wild type and human A30P mutant α-synuclein mice

Keane, P. C., Hanson, P. S., Patterson, L., Blain, P. G., Hepplewhite, P. D., Khundakar, A. A., Judge, S. J., Kahle, P. J., LeBeau, F. E. N., & Morris, C. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134437 · Cited by 36 · see citing works

Neurotoxin-Induced Rodent Models of Parkinson’s Disease: Benefits and Drawbacks

El‐Gamal, M., Salama, M., Collins‐Praino, L. E., Baetu, I., Fathalla, A. M., Soliman, A. M., Mohamed, W. M. Y., & Moustafa, A. A. (2021) · Neurotoxicity Research · doi:10.1007/s12640-021-00356-8 · Cited by 36 · see citing works

Emerging evidence for the neuroprotective role of α-synuclein

Lee, H., Zhu, X., Takeda, A., Perry, G. L., & Smith, M. A. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.04.024 · Cited by 33 · see citing works

Alpha-synuclein: between synaptic function and dysfunction.

Rosa, G. D., Puzzo, D., Sant'Angelo, A., Trinchese, F., & Arancio, O. (2003) · PubMed · doi:10.14670/hh-18.1257 · Cited by 31 · see citing works

Dopamine-depletion and increased α-synuclein load induce degeneration of cortical cholinergic fibers in mice

Szegő, É. M., Gerhardt, E., Outeiro, T. F., & Kermer, P. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.06.048 · Cited by 29 · see citing works

Modulation of α-synuclein expression in transgenic animals for modelling synucleinopathies — is the juice worth the squeeze?

Buchman, V. L., & Ninkina, N. N. (2008) · Neurotoxicity Research · doi:10.1007/bf03033857 · Cited by 29 · see citing works

Genome-Wide Microarray Analysis of the Differential Neuroprotective Effects of Antioxidants in Neuroblastoma Cells Overexpressing the Familial Parkinson’s Disease α-Synuclein A53T Mutation

Ma, L., Cao, T. T., Kandpal, G., Warren, L., Hess, J. F., Seabrook, G. R., & Ray, W. J. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0038-1 · Cited by 27 · see citing works

Chromosomal Loci Influencing the Susceptibility to the Parkinsonian Neurotoxin 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine

Sedelis, M., Hofele, K., Schwarting, R. K. W., Huston, J. P., & Belknap, J. K. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-23-08247.2003 · Cited by 27 · see citing works

Anti-apoptotic gene therapy in Parkinson’s disease

Schulz, J. B. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_70 · Cited by 26 · see citing works

A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice

Szegő, É. M., Gerhardt, E., Kermer, P., & Schulz, J. B. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.017 · Cited by 24 · see citing works

MPTP-induced vulnerability of dopamine neurons in A53T α-synuclein overexpressed mice with the potential involvement of DJ-1 downregulation

Lee, S., Oh, S. T., Jeong, H. J., Pak, S. C., Park, H., Kim, J., Cho, H., & Jeon, S. (2017) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2017.21.6.625 · Cited by 24 · see citing works

Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain‐derived neurotrophic factor

Komnig, D., Dagli, T. C., Habib, P., Zeyen, T., Schulz, J. B., & Falkenburger, B. H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14575 · Cited by 24 · see citing works

Will Preventing Protein Aggregates Live Up to Its Promise as Prophylaxis Against Neurodegenerative Diseases?

Lee, H., Petersen, R. B., Zhu, X., Honda, K., Aliev, G. M., Smith, M. A., & Perry, G. L. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00491.x · Cited by 24 · see citing works

Environmental Toxins and α-Synuclein in Parkinson's Disease

Liu, Y., & Yang, H. (2005) · Molecular Neurobiology · doi:10.1385/mn:31:1-3:273 · Cited by 23 · see citing works

Identification of Allele-Specific RNAi Effectors Targeting Genetic Forms of Parkinson's Disease

Sibley, C. R., & Wood, M. J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026194 · Cited by 22 · see citing works

Lewy Body Disorders

Jellinger, K. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-30377-2_15 · Cited by 21 · see citing works

Impact of fatty acid-binding proteins and dopamine receptors on α-synucleinopathy

Kawahata, K., & Fukunaga, K. (2021) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2021.12.003 · Cited by 20 · see citing works

Literature-Related Discovery (LRD)

Kostoff, R. N., Block, J. A., Solka, J. L., Briggs, M. B., Rushenberg, R. L., Stump, J. A., Johnson, D., Lyons, T. J., & Wyatt, J. R. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada473438 · Cited by 19 · see citing works

Visualization of early oligomeric α‐synuclein pathology and its impact on the dopaminergic system in the (Thy‐1)‐h[A30P]α‐syn transgenic mouse model

Behere, A., Thörnqvist, P., Winberg, S., Ingelsson, M., Bergström, J. J. E., & Ekmark‐Lewén, S. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24927 · Cited by 18 · see citing works

Engineered modeling and the secrets of Parkinson's disease

Vila, M., Wu, D. C., & Przedborski, S. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01984-6 · Cited by 18 · see citing works

Mechanisms and models of α-synuclein-related neurodegeneration

Springer, W., & Kahle, P. J. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-996-0025-8 · Cited by 16 · see citing works

Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains

Piltonen, M., Savolainen, M. H., Patrikainen, S., Baekelandt, V., Myöhänen, T. T., & Männistö, P. T. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.11.045 · Cited by 15 · see citing works

A β-Wrapin Targeting the N-Terminus of α-Synuclein Monomers Reduces Fibril-Induced Aggregation in Neurons

Szegő, É. M., Szegő, É. M., Boß, F., Komnig, D., Gärtner, C., Höfs, L., Shaykhalishahi, H., Wördehoff, M., Saridaki, T., Schulz, J. B., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.696440 · Cited by 15 · see citing works

Increased sensitivity to MPTP in human α-synuclein A30P transgenic mice

Nieto, M., Gil-Bea, F. J., Dalfó, E., Cuadrado‐Tejedor, M., Cabodevilla, F., Sánchez, B., Catena, S., Sesma, T., Ribé, E. M., Ferrer, I., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.010 · Cited by 100 · see citing works

Increased Dopaminergic Neuron Sensitivity to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Transgenic Mice Expressing Mutant A53T α-Synuclein

Yu, W. H., Matsuoka, Y., Sziráki, I., Hashim, A., LaFrancois, J. J., Sershen, H. W., & Duff, K. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9533-4 · Cited by 41 · see citing works

Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice

Schlüter, O. M., Fornai, F., Alessandri, M., TAKAMORI, S., Geppert, M., Jahn, R., & Südhof, T. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00036-8 · Cited by 145 · see citing works

Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP

Dauer, W. T., Kholodilov, N. G., Vila, M., Trillat, A., Goodchild, R. E., Larsen, K. E., Staal, R. G. W., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172514599 · Cited by 580 · see citing works

Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice

Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285 · see citing works